Skip to main content

Payers' Guide

Payers' Guide, FDA Approvals

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

Payers' Guide, FDA Approvals

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

Lisa A. Raedler, PhD, RPh

Foreward - The Fifth Annual Payers’ Guide to New FDA Approvals

Introduction - New FDA Drug Approvals in 2013

Gary M. Owens, MD

FDA Approvals of Brand-Name Prescription Drugs in 2013

Specialty Drugs Top the Trends in the 2014 Pipeline

Dalia Buffery, MA, ABD

Abraxane (nab-Paclitaxel) Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer

Lisa A. Raedler, PhD, RPh

Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension

Lisa A. Raedler, PhD, RPh

Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation

Anoro Ellipta (Umeclidinium/Vilanterol): First Dual Long-Acting Inhaler for Long-Term Maintenance Treatment of COPD

Lisa A. Raedler, PhD, RPh

Page 14 of 19
Results 131 - 140 of 185